LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported positive results from Phase 2 trials of LB-102 in schizophrenia, initiated pivotal Phase 3 and additional Phase 2 trials for bipolar depression and major depressive disorder, and announced a $100 million private placement. The company has a strong cash position of $295.2 million as of December 31, 2025, providing a runwa…